An examination of health care utilization during the COVID-19 pandemic among women with early-stage hormone receptor-positive breast cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1472-6963
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
An examination of health care utilization during the COVID-19 pandemic among women with early-stage hormone receptor-positive breast cancer ; volume:22 ; number:1 ; day:23 ; month:11 ; year:2022 ; pages:1-8 ; date:12.2022
BMC health services research ; 22, Heft 1 (23.11.2022), 1-8, 12.2022
- Urheber
-
Paladino, Andrew J.
Pebley, Kinsey
Kocak, Mehmet
Krukowski, Rebecca A.
Waters, Teresa M.
Vidal, Gregory
Schwartzberg, Lee
Curry, Andrea N.
Graetz, Ilana
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12913-022-08705-9
- URN
-
urn:nbn:de:101:1-2023020509005995220320
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:02 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Paladino, Andrew J.
- Pebley, Kinsey
- Kocak, Mehmet
- Krukowski, Rebecca A.
- Waters, Teresa M.
- Vidal, Gregory
- Schwartzberg, Lee
- Curry, Andrea N.
- Graetz, Ilana
- SpringerLink (Online service)
Ähnliche Objekte (12)
Rat Models of Hormone Receptor-Positive Breast Cancer
The 21-gene recurrence score complements IBTR! Estimates in early-stage, hormone receptor-positive, HER2-normal, lymph node-negative breast cancer
Immunotherapy for hormone receptor‒positive HER2-negative breast cancer
Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer
Using Oncotype DX breast recurrence score® assay to define the role of neoadjuvant endocrine therapy in early-stage hormone receptor-positive breast cancer
Persistence to extended adjuvant endocrine therapy following Breast Cancer Index (BCI) testing in women with early-stage hormone receptor-positive (HR +) breast cancer
Quantitative Biomarkers, Genomic Assays, and Demographics Associated with Breast-Conserving Surgery Following Neoadjuvant Therapy in Early-Stage, Hormone Receptor-Positive, HER-Negative Breast Cancer
EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer
Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
Mismatch repair-deficient hormone receptor-positive breast cancers: Biology and pathological characterization
SABCS 2017: lifestyle factors, hormone receptor-positive advanced disease, liquid biopsies, and prognosis
Comparative biological activity of palbociclib and ribociclib in hormone receptor-positive breast cancer
Rat Models of Hormone Receptor-Positive Breast Cancer
The 21-gene recurrence score complements IBTR! Estimates in early-stage, hormone receptor-positive, HER2-normal, lymph node-negative breast cancer
Immunotherapy for hormone receptor‒positive HER2-negative breast cancer
Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer
Using Oncotype DX breast recurrence score® assay to define the role of neoadjuvant endocrine therapy in early-stage hormone receptor-positive breast cancer
Persistence to extended adjuvant endocrine therapy following Breast Cancer Index (BCI) testing in women with early-stage hormone receptor-positive (HR +) breast cancer
Quantitative Biomarkers, Genomic Assays, and Demographics Associated with Breast-Conserving Surgery Following Neoadjuvant Therapy in Early-Stage, Hormone Receptor-Positive, HER-Negative Breast Cancer
EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer
Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
Mismatch repair-deficient hormone receptor-positive breast cancers: Biology and pathological characterization
SABCS 2017: lifestyle factors, hormone receptor-positive advanced disease, liquid biopsies, and prognosis
Comparative biological activity of palbociclib and ribociclib in hormone receptor-positive breast cancer
Rat Models of Hormone Receptor-Positive Breast Cancer
The 21-gene recurrence score complements IBTR! Estimates in early-stage, hormone receptor-positive, HER2-normal, lymph node-negative breast cancer
Immunotherapy for hormone receptor‒positive HER2-negative breast cancer
Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer
Using Oncotype DX breast recurrence score® assay to define the role of neoadjuvant endocrine therapy in early-stage hormone receptor-positive breast cancer
Persistence to extended adjuvant endocrine therapy following Breast Cancer Index (BCI) testing in women with early-stage hormone receptor-positive (HR +) breast cancer
Quantitative Biomarkers, Genomic Assays, and Demographics Associated with Breast-Conserving Surgery Following Neoadjuvant Therapy in Early-Stage, Hormone Receptor-Positive, HER-Negative Breast Cancer
EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer
Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
Mismatch repair-deficient hormone receptor-positive breast cancers: Biology and pathological characterization
SABCS 2017: lifestyle factors, hormone receptor-positive advanced disease, liquid biopsies, and prognosis